Envista (NYSE:NVST) Price Target Raised to $22.00 at Jefferies Financial Group

Envista (NYSE:NVST) had its price objective raised by investment analysts at Jefferies Financial Group from $20.00 to $22.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “hold” rating on the stock. Jefferies Financial Group’s price target would indicate a potential upside of 4.35% from the stock’s current price.

Other equities analysts have also recently issued reports about the company. Leerink Partnrs raised Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Stifel Nicolaus lifted their price target on shares of Envista from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Piper Sandler upped their price objective on shares of Envista from $16.00 to $17.00 and gave the company a “neutral” rating in a research note on Thursday, October 31st. Leerink Partners upgraded Envista from an “underperform” rating to a “market perform” rating and raised their price objective for the stock from $16.00 to $23.00 in a report on Thursday, October 31st. Finally, Robert W. Baird lifted their price target on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Envista presently has an average rating of “Hold” and an average target price of $20.13.

Envista Price Performance

NVST stock traded up $0.03 during midday trading on Thursday, hitting $21.08. 377,694 shares of the stock were exchanged, compared to its average volume of 1,713,624. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.08. The stock has a market cap of $3.63 billion, a price-to-earnings ratio of -2.72, a PEG ratio of 1.83 and a beta of 1.33. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $24.79. The stock’s 50-day moving average price is $19.99 and its 200-day moving average price is $18.78.

Envista (NYSE:NVST) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The firm had revenue of $601.00 million for the quarter, compared to analysts’ expectations of $590.34 million. During the same period in the prior year, the company earned $0.43 EPS. The firm’s revenue was down 4.8% on a year-over-year basis. Research analysts predict that Envista will post 0.72 earnings per share for the current year.

Hedge Funds Weigh In On Envista

A number of hedge funds have recently added to or reduced their stakes in the business. Iron Triangle Partners LP bought a new stake in shares of Envista during the 3rd quarter worth about $43,262,000. Point72 Asset Management L.P. acquired a new position in shares of Envista during the third quarter valued at approximately $37,559,000. Polar Asset Management Partners Inc. raised its holdings in Envista by 375.6% during the third quarter. Polar Asset Management Partners Inc. now owns 1,497,250 shares of the company’s stock worth $29,586,000 after purchasing an additional 1,182,450 shares in the last quarter. Ariel Investments LLC lifted its position in Envista by 11.0% in the second quarter. Ariel Investments LLC now owns 9,871,152 shares of the company’s stock worth $164,157,000 after purchasing an additional 978,952 shares during the period. Finally, Franklin Resources Inc. boosted its stake in Envista by 26.5% during the 3rd quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock valued at $78,480,000 after purchasing an additional 830,861 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.